The Biopharmaceutical sector has been changing very rapidly from monoclonal antibodies to cell and gene therapy and RNA-based therapeutics. The growing healthcare needs demand cost-effective and rapid manufacturing technologies. The approval of biosimilars and continuous manufacturing has joined hands with manufacturers to meet these demands. This shift from fixed stainless steel to single-use systems (SUS) has revolutionized the therapeutic market. The rapid market growth for SUS, composed primarily of plastic components that are sealed and sterilized using gamma irradiation, is expected to continue. This webinar will focus on product development, including sterilization and lab-testing strategies, to help ensure that there is no contamination in the development and manufacturing of SUS to promote end-user safety.